Viatris Inc.

VTRS Healthcare Drug Manufacturers Specialty & Generic

Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue grew 4.88%, EPS fell 2,464.1%, free cash flow grew 101.1% and total debt fell 18.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years.

18.66 0.44 +2.41%
Market cap
$20.9B
P/E
0.0×
Fwd P/E
61.1×
Dividend yield
2.57%
F-score
4/9
Altman Z
0.61
Beneish M
−3.29
Dividend safety
37/100

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Total current assets
9,951.40 9,789.20 10,916.80 10,055.70
Total non-current assets
27,969.00 27,403.90 25,917.80 24,988.90
Total Assets
37,920.40 37,193.10 36,834.60 35,044.60
Total current liabilities
7,364.10 7,094.30 6,810.30 6,345.80
Total non-current liabilities
15,338.70 15,387.50 15,366.60 14,438.40
Total liabilities
22,702.80 22,481.80 22,176.90 20,784.20
Common Equity (Total)
15,217.60 14,711.30 14,657.70 14,260.40
Shareholders Equity (Total)
15,217.60 14,711.30 14,657.70 14,260.40
Total Debt
16,262.40 14,413.90 14,344.60 13,351.30

Show all line items

In millions of $ except per-share values · columns are period end dates